Clinical Trial Update: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing pharmacokinetics, efficacy, and safety of 10% intravenous immunoglobulin in patients with primary immunodeficiency disease has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• IVIg 10% (intravenous immunoglobulin)

Snippet

Sponsor: Kedrion S.p.A. | Conditions: Primary Immunodeficiency Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-01-27